Integra LifeSciences updated presentation materials for use with existing and prospective lenders as it plans to refinance its outstanding senior Credit Facility in 2026. The materials matter to investors because they outline the information the company intends to present during refinancing discussions, while limiting distribution to qualified institutional buyers and non-U.S. persons.
Key Highlights
- The presentation is available only to qualified institutional buyers and non-U.S. Persons.
- Integra describes Specialty Surgery and Tissue Reconstruction as its two operating segments.
- The materials include non-GAAP measures such as adjusted EBITDA, free Cash Flow and net debt.
Integra LifeSciences Holdings Corp (NASDAQ: IART) has updated its investor presentation for discussions with existing and prospective lenders tied to refinancing its outstanding senior credit facility in 2026. The materials may be used periodically during those lender presentations.
Updated Materials Outline Refinancing Plans
The presentation is dated September 8, 2026, and is restricted to qualified institutional buyers and non-U.S. Persons. Integra describes its Business through Specialty Surgery and Tissue Reconstruction. The materials state that 2026 is a key inflection period as Integra progresses through FDA-mandated Manufacturing and quality-system remediation. They also include forward-looking statements concerning operational and financial performance, strategic initiatives, manufacturing, product development, regulatory approvals and quality-system compliance. The presentation identifies risks including geopolitical tension, trade restrictions, supply-chain disruption, interest-rate and foreign-currency fluctuations, regulatory delays, manufacturing interruptions, competition, reimbursement decisions and the company’s assessment of flooding at its Cincinnati, Ohio, manufacturing facility. Integra also defines non-GAAP measures including organic revenues, adjusted EBITDA, adjusted gross profit, free cash flow and net debt.
FAQs
Q: What is Integra LifeSciences refinancing in 2026?
A: Integra LifeSciences plans to refinance its outstanding senior credit facility during 2026. Its updated investor presentation is intended for discussions with existing and prospective lenders.
Q: Who can access Integra LifeSciences’ investor presentation?
A: The presentation is available only to qualified institutional buyers and non-U.S. Persons. Integra says the materials contain public information or information derivable from public sources.
Q: What financial measures appear in Integra’s presentation?
A: The materials define non-GAAP measures including adjusted EBITDA, adjusted gross profit, free cash flow, net debt and organic revenues. Reconciliations appear in the presentation appendix.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.